ClinicalTrials.gg

Program

trilaciclib

Also written as “Trilaciclib” and “Trilaciclib, carboplatin, etoposide,or Topotecan”.

Its studies are mostly in Small Cell Lung Carcinoma · Triple Negative Breast Neoplasms · Carcinoma, Transitional Cell · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Furthest: phase 4, since Apr 12, 202314 company-led studies, 3 open or runningNext primary completion: Jul 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pharmacosmos112 open or runningphase 4since Apr 12, 2023Jul 8, 2015Oct 31, 2027phase 3 · NCT07473128
Simcere Pharmaceutical Group31 open or runningphase 4since Sep 28, 2021May 8, 2021Jul 15, 2027phase 3 · NCT07881705

Also a collaborator on its studies: roche-genentech.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 8, 2015First studies: 2 phase 2 studies in Small Cell Lung CarcinomaNew to PharmacosmosPharmacosmos · NCT02499770, NCT02514447
  2. Feb 1, 2017Phase 2 study in Small Cell Lung CarcinomaPharmacosmos · NCT03041311 · 107 enrolled · United States, Bulgaria, Estonia and more
  3. Oct 20, 2020Phase 3 study in Colorectal NeoplasmsPharmacosmos · NCT04607668 · 326 enrolled · United States, China, Hungary and more
  4. Feb 18, 2021Phase 3 study in Triple Negative Breast NeoplasmsPharmacosmos · NCT04799249 · 194 enrolled · United States, Australia, Bulgaria and more
  5. Apr 16, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungPharmacosmos · NCT04863248 · 10 enrolled · United States
  6. May 5, 2021Phase 2 study in Carcinoma, Transitional CellPharmacosmos · NCT04887831 · 92 enrolled · United States, France, Georgia and more
  7. May 8, 2021Simcere Pharmaceutical Group's first study: phase 3 study in Small Cell Lung CarcinomaNew to Simcere Pharmaceutical GroupSimcere Pharmaceutical Group · NCT04902885 · 95 enrolled · China
  8. Sep 28, 2021Phase 4 study in Small Cell Lung CarcinomaSimcere Pharmaceutical Group · NCT05071703 · 30 enrolled · China
  9. Oct 6, 20212 phase 2 studies in Triple Negative Breast NeoplasmsPharmacosmos · NCT05112536, NCT05113966
  10. Apr 12, 2023Phase 4 study in Small Cell Lung CarcinomaPharmacosmos · NCT05874401 · 302 enrolled · Spain
  11. Mar 5, 2026Phase 3 study in Limited Stage Small Cell Lung CancerPharmacosmos · NCT07473128 · 120 planned · United States
  12. Oct 2, 2026Primary completion moved from 2027-06 to 2027-10-31Date moved laterphase 3 · +5 months · NCT07473128
  13. Oct 5, 2026Primary completion moved from 2027-10-30 to 2028-02-05Date moved laterphase 4 · +3 months · NCT05874401
  14. Oct 12, 2026Phase 3 study in Small Cell Lung CarcinomaSimcere Pharmaceutical Group · NCT07881705 · 106 enrolled · China

Ahead

  1. Jul 15, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaSimcere Pharmaceutical Group · NCT07881705
  2. Oct 31, 2027Primary completion: phase 3 study in Limited Stage Small Cell Lung CancerPharmacosmos · NCT07473128
  3. Feb 5, 2028Primary completion: phase 4 study in Small Cell Lung CarcinomaPharmacosmos · NCT05874401

TargetBeta

CDK4 →CDK6 →read by rule
“A small molecule, competitive inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), ”NCIt, by rule
“Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor; Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
abemaciclibruleEli Lillyphase 449
palbociclibrulePfizerphase 436
culmerciclibSino Biopharmaceuticalphase 311
narazaciclibrulehangzhou-hanx-biopharmaceuticals-ltdphase 24
vustanaciclibregor-pharmaceuticals-incphase 23

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07881705Small Cell Lung Carcinoma · China3Active, not recruitingSimcere Pharmaceutical GroupJul 15, 2027106
NCT07473128Limited Stage Small Cell Lung Cancer · United States3RecruitingPharmacosmosOct 31, 2027120
NCT05874401Small Cell Lung Carcinoma · Spain4Active, not recruitingPharmacosmosFeb 5, 2028302
NCT05113966Triple Negative Breast Neoplasms · United States2TerminatedPharmacosmosNov 10, 202330
NCT05112536Triple Negative Breast Neoplasms · United States2CompletedPharmacosmosOct 31, 202224
NCT05071703Small Cell Lung Carcinoma · China4CompletedSimcere Pharmaceutical GroupApr 10, 202230
NCT04902885Small Cell Lung Carcinoma · China3CompletedSimcere Pharmaceutical GroupDec 29, 202195
NCT04887831Carcinoma, Transitional Cell · United States, France, Georgia and more2TerminatedPharmacosmosApr 7, 202392
NCT04863248Carcinoma, Non-Small-Cell Lung · United States2TerminatedPharmacosmosFeb 2, 202210
NCT04799249Triple Negative Breast Neoplasms · United States, Australia, Bulgaria and more3CompletedPharmacosmosMay 24, 2024194
NCT04607668Colorectal Neoplasms · United States, China, Hungary and more3TerminatedPharmacosmosFeb 13, 2023326
NCT03041311Small Cell Lung Carcinoma · United States, Bulgaria, Estonia and more2CompletedPharmacosmosAug 17, 2018107
NCT02514447Small Cell Lung Carcinoma · United States, Belgium, Bosnia and Herzegovina and more2CompletedPharmacosmosSep 28, 2018123
NCT02499770Small Cell Lung Carcinoma · United States, France, Georgia and more2CompletedPharmacosmosJul 3, 2017122

How it is read

Names in the registry

  • “Trilaciclib”, 13 entries
  • “Trilaciclib, carboplatin, etoposide,or Topotecan”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.